Literature DB >> 17928090

The clinical significance of persistently normal ALT in chronic hepatitis B infection.

Michelle Lai1, Benjamin J Hyatt, Imad Nasser, Michael Curry, Nezam H Afdhal.   

Abstract

BACKGROUND/AIMS: Chronic hepatitis B virus (HBV) disease is caused by both necroinflammation and active viral replication. The role of ALT levels as a predictor of liver injury has recently been questioned. The aim of the study was to determine whether normal ALT is associated with liver injury in a cohort of HBV patients undergoing liver biopsy.
METHODS: This is a retrospective review of chronic HBV patients divided into 3 groups; (1) persistently normal ALT (PNALT); (2) ALT 1-1.5X ULN and (3) ALT>1.5X ULN. Multiple clinical, biochemical, virological variables were evaluated.
RESULTS: One hundred and ninety-two patients met the inclusion criteria, 59 with PNALT, 26 with ALT 1-1.5X ULN, and 107 with ALT>1.5X ULN. Increasing age, higher ALT, higher grade of inflammation on biopsy, and HBeAg positivity predicted fibrosis. 18% of patients with PNALT had stage 2+ fibrosis and 34% had grade 2 or 3 inflammation. Overall 37% of patients with PNALT had significant fibrosis or inflammation. Subgroup analysis showed the majority with fibrosis belonged to the high normal ALT group and that only a minority who were young and immune tolerant had significant findings on biopsy.
CONCLUSIONS: There is significant fibrosis and inflammation in 37% of patients with PNALT and a liver biopsy should be considered in patients older than 40 with high normal ALT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928090     DOI: 10.1016/j.jhep.2007.07.022

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  96 in total

Review 1.  Occult hepatitis B: clinical implications and treatment decisions.

Authors:  Paul Schmeltzer; Kenneth E Sherman
Journal:  Dig Dis Sci       Date:  2010-10-07       Impact factor: 3.199

2.  Trends in the indication and method of liver biopsy for hepatitis B and C.

Authors:  Michael J Lipp; Lionel S D'Souza; David J Clain; Henry C Bodenheimer; Albert D Min
Journal:  Dig Dis Sci       Date:  2010-07-15       Impact factor: 3.199

3.  Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines.

Authors:  Moon Seok Choi; Byung Chul Yoo
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

4.  Characteristics of chronic hepatitis B patients who underwent liver biopsies.

Authors:  W Chotiyaputta; B Degertekin; B J McKenna; N Samala; R J Fontana; A S F Lok
Journal:  J Viral Hepat       Date:  2010-08-17       Impact factor: 3.728

Review 5.  Antiviral therapies and prospects for a cure of chronic hepatitis B.

Authors:  Fabien Zoulim; David Durantel
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

6.  Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics.

Authors:  Kevin C Ku; Jiayi Li; Nghi B Ha; Marina Martin; Vincent G Nguyen; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-12       Impact factor: 3.199

7.  The clinical value of serum connective tissue growth factor in the assessment of liver fibrosis.

Authors:  Dai Zhang; Nian-Yue Wang; Cheng-Bao Yang; Guo-Xiang Fang; Wei Liu; Jian Wen; Chan Luo
Journal:  Dig Dis Sci       Date:  2009-03-18       Impact factor: 3.199

8.  A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection.

Authors:  Myron John Tong; Leeyen Hsu; Carlos Hsien; Jia-Horng Kao; Francisco Antonio Durazo; Sammy Saab; Lawrence Mitchell Blatt
Journal:  Hepatol Int       Date:  2010-04-07       Impact factor: 6.047

9.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Authors:  Yun-Fan Liaw; Nancy Leung; Jia-Horng Kao; Teerha Piratvisuth; Edward Gane; Kwang-Hyub Han; Richard Guan; George K K Lau; Stephen Locarnini
Journal:  Hepatol Int       Date:  2008-05-10       Impact factor: 6.047

10.  Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

Authors:  Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2010-02-20       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.